MeHow Innovative Ltd. A vs Integer: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

MeHow Innovative Ltd. A (301363.CS)

Q3 202627 Jul – 22 Sep 2026

▲3

BCI patent and client tie-ups drive MeHow; H1 profit up 8.8%

BCI patent strengthens technology position MeHow published a patent for a self-generating neural electrode that tackles long-term implant problems like rising impedance and weakening signals. This keeps it central to invasive brain-computer interface hardware, a fast-growing niche, and supports future demand for its electrode components.
A company-specific technology milestone that directly boosts its competitive position in the BCI supply chain.
Technical cooperation with domestic BCI clients MeHow said it is working closely with domestic brain-computer interface customers, helping them move from lab testing to large-scale commercial production. This positions the company to benefit as the BCI industry shifts from research to real sales, adding a new growth driver beyond its core medical device business.
Shows concrete commercial progress with BCI clients, a key new demand source for the company.
First-half profit rises 8.8% on higher revenue MeHow reported H1 net profit of 124 million yuan, up 8.8%, and revenue of 813 million yuan, up 11.0%. Operating cash flow jumped 48.3%, showing the core business is healthy and generating more cash, which supports the stock's fundamental value.
The interim results confirm steady earnings growth and strong cash generation, a core support for the share price.
Restricted share incentive plan at 8.49 yuan MeHow plans to grant 6.07 million restricted shares to up to 496 core employees at 8.49 yuan each. This ties staff to the company's long-term success, a positive for retention, but the low grant price can dilute existing shareholders and may cap near-term upside.
A new equity event that affects ownership and employee alignment, with both supportive and dilutive effects.

August 202627 Jul – 22 Sep 2026

▲3

BCI patent and client tie-ups drive MeHow; H1 profit up 8.8%

BCI patent strengthens technology position MeHow published a patent for a self-generating neural electrode that tackles long-term implant problems like rising impedance and weakening signals. This keeps it central to invasive brain-computer interface hardware, a fast-growing niche, and supports future demand for its electrode components.
A company-specific technology milestone that directly boosts its competitive position in the BCI supply chain.
Technical cooperation with domestic BCI clients MeHow said it is working closely with domestic brain-computer interface customers, helping them move from lab testing to large-scale commercial production. This positions the company to benefit as the BCI industry shifts from research to real sales, adding a new growth driver beyond its core medical device business.
Shows concrete commercial progress with BCI clients, a key new demand source for the company.
First-half profit rises 8.8% on higher revenue MeHow reported H1 net profit of 124 million yuan, up 8.8%, and revenue of 813 million yuan, up 11.0%. Operating cash flow jumped 48.3%, showing the core business is healthy and generating more cash, which supports the stock's fundamental value.
The interim results confirm steady earnings growth and strong cash generation, a core support for the share price.
Restricted share incentive plan at 8.49 yuan MeHow plans to grant 6.07 million restricted shares to up to 496 core employees at 8.49 yuan each. This ties staff to the company's long-term success, a positive for retention, but the low grant price can dilute existing shareholders and may cap near-term upside.
A new equity event that affects ownership and employee alignment, with both supportive and dilutive effects.

Latest27 Jul – 22 Sep 2026

▲3

BCI patent and client tie-ups drive MeHow; H1 profit up 8.8%

BCI patent strengthens technology position MeHow published a patent for a self-generating neural electrode that tackles long-term implant problems like rising impedance and weakening signals. This keeps it central to invasive brain-computer interface hardware, a fast-growing niche, and supports future demand for its electrode components.
A company-specific technology milestone that directly boosts its competitive position in the BCI supply chain.
Technical cooperation with domestic BCI clients MeHow said it is working closely with domestic brain-computer interface customers, helping them move from lab testing to large-scale commercial production. This positions the company to benefit as the BCI industry shifts from research to real sales, adding a new growth driver beyond its core medical device business.
Shows concrete commercial progress with BCI clients, a key new demand source for the company.
First-half profit rises 8.8% on higher revenue MeHow reported H1 net profit of 124 million yuan, up 8.8%, and revenue of 813 million yuan, up 11.0%. Operating cash flow jumped 48.3%, showing the core business is healthy and generating more cash, which supports the stock's fundamental value.
The interim results confirm steady earnings growth and strong cash generation, a core support for the share price.
Restricted share incentive plan at 8.49 yuan MeHow plans to grant 6.07 million restricted shares to up to 496 core employees at 8.49 yuan each. This ties staff to the company's long-term success, a positive for retention, but the low grant price can dilute existing shareholders and may cap near-term upside.
A new equity event that affects ownership and employee alignment, with both supportive and dilutive effects.

Integer Holdings Corp (ITGR)

Q3 202617 Jul – 29 Sep 2026

▲1▼1

KKR's $127/share buyout drives ITGR, with approval risk remaining

KKR buyout at $127 per share KKR agreed to buy Integer for $127 per share in cash, a $5.7 billion deal at a 51.8% premium. The stock now trades near the offer, so price reflects the deal, not company performance.
This is the dominant new event that now defines ITGR's stock price.
Deal approval still pending Financing is secured, but the deal still needs shareholder and regulatory approval. Analysts downgraded to neutral, and fair-value estimates of $112–$139 sit around the offer, showing limited upside unless a higher bid emerges.
It explains the main remaining risks and why the stock trades near the offer.
Weak Q2 results and withdrawn guidance Q2 profit fell to $23.6 million from $37 million, revenue slipped 2.6%, and gross margin narrowed to 24.3%. Management withdrew guidance and canceled its earnings call, removing forward-looking data for investors.
It is the key counterweight showing underlying business weakness behind the deal.
Investor-rights review may seek higher bid An investor-rights law firm is reviewing whether $127 is fair and may seek a higher bid. This creates a small chance of a bump, but also adds uncertainty around the deal's final price.
It highlights a potential upside catalyst and a source of deal uncertainty.

August 20263 Aug – 29 Sep 2026

▲1▼1

KKR's $127 Cash Buyout Sets ITGR's Price, Despite Weak Q2

KKR buyout locks in $127 cash per share Integer agreed to be bought by KKR for $127 per share in cash, a $5.7 billion deal. That price now anchors the stock, because shareholders expect to receive it when the deal closes. The buyer already has financing, so the main remaining hurdles are a shareholder vote and regulatory approvals.
The buyout is the single force now setting ITGR's price and the main answer to why it moves.
Weak Q2 profit and sales, margins squeezed Second-quarter profit fell to $23.61 million from $37.01 million, and revenue slipped 2.6% to $464.1 million. Gross margin shrank to 24.3% from 27.1%. This weak operating picture is a counterweight: it shows the business was softening even as the buyout price caps the stock.
It is the main negative fundamental fact and the real counterweight to the buyout.
Company drops guidance and earnings call Integer withdrew its financial outlook and canceled its quarterly earnings call, saying merger progress now matters more than operating targets. For investors this removes forward-looking numbers, so the stock trades on deal news rather than company performance. It also signals management is focused on closing the KKR sale.
It explains why ordinary operating news no longer drives the stock and why the deal dominates.
Law firm review may seek a higher price An investor-rights law firm is investigating whether the $127-per-share KKR sale is fair and may push for more money or extra disclosures. Such reviews are common in buyouts. If they lead to a raised bid, the stock could rise above $127; if not, they are mostly noise.
It is the only new event that could change the deal price, so it matters to the buyout story.

Latest3 Aug – 29 Sep 2026

▲1▼1

KKR's $127 Cash Buyout Sets ITGR's Price, Despite Weak Q2

KKR buyout locks in $127 cash per share Integer agreed to be bought by KKR for $127 per share in cash, a $5.7 billion deal. That price now anchors the stock, because shareholders expect to receive it when the deal closes. The buyer already has financing, so the main remaining hurdles are a shareholder vote and regulatory approvals.
The buyout is the single force now setting ITGR's price and the main answer to why it moves.
Weak Q2 profit and sales, margins squeezed Second-quarter profit fell to $23.61 million from $37.01 million, and revenue slipped 2.6% to $464.1 million. Gross margin shrank to 24.3% from 27.1%. This weak operating picture is a counterweight: it shows the business was softening even as the buyout price caps the stock.
It is the main negative fundamental fact and the real counterweight to the buyout.
Company drops guidance and earnings call Integer withdrew its financial outlook and canceled its quarterly earnings call, saying merger progress now matters more than operating targets. For investors this removes forward-looking numbers, so the stock trades on deal news rather than company performance. It also signals management is focused on closing the KKR sale.
It explains why ordinary operating news no longer drives the stock and why the deal dominates.
Law firm review may seek a higher price An investor-rights law firm is investigating whether the $127-per-share KKR sale is fair and may push for more money or extra disclosures. Such reviews are common in buyouts. If they lead to a raised bid, the stock could rise above $127; if not, they are mostly noise.
It is the only new event that could change the deal price, so it matters to the buyout story.

July 202617 Jul – 6 Aug 2026

▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.
This is the single new event that now sets ITGR's price, so it is the core answer.
No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.
Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.
Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.
Gives the honest counterweight: upside is limited and tied to completion, not to the business.
Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.
It is the only negative force this period, but the buyout has largely overtaken it.

17 Jul – 6 Aug 2026

▲2▼1

KKR's $127-a-share buyout deal is now the whole story for ITGR

KKR agrees to buy Integer for $127 a share KKR signed a definitive deal to take Integer private for $127 a share in cash, about $5.7 billion, a 51.8% premium to the price before the strategic review. The stock jumped toward the offer, and the deal is expected to close by year-end.
This is the single new event that now sets ITGR's price, so it is the core answer.
No financing risk, but a vote and regulators must clear it The buyer needs no financing, so the main risks are stockholders approving the deal and regulators clearing it. If it closes, Integer leaves the New York Stock Exchange and becomes privately held, so the shares stop trading publicly.
Explains the real conditions and counterweight behind the agreed deal, which readers need to judge it.
Analysts cut ratings; fair-value estimates still sit below the offer After the deal, analysts downgraded the stock to neutral, saying further gains depend on the deal closing. One fair-value estimate rose to $112.14, still under the $127 offer, while another model says $139. This shows the price is now pinned near the deal terms, not company performance.
Gives the honest counterweight: upside is limited and tied to completion, not to the business.
Insurance-driven procedure slowdown is now a side issue An Intuitive Surgical warning that insurance changes could slow U.S. procedures briefly dragged medical device stocks down, including Integer. With the buyout agreed, this demand worry matters far less to the price than the deal itself.
It is the only negative force this period, but the buyout has largely overtaken it.